Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 8/20 | 0.49 |
| ▸ | GRM5 | P41594 | 3/20 | 0.49 |
| ▸ | SPR | P35270 | 7/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22634389 | 0.98 | HSD11B1 (0.46) | HSD11B1GRM5SPRUSP2 | |
| SCHEMBL22158069 | 0.94 | SPR (0.47) | HSD11B1GRM5SPRUSP2 | |
| SCHEMBL31187309 | 0.92 | GRM5 (0.58) | HSD11B1GRM5SPRUSP2 | |
| SCHEMBL21223637 | 0.89 | GRM5 (0.55) | HSD11B1GRM5SPRUSP2 | |
| SCHEMBL30553460 | 0.89 | SPR (0.40) | HSD11B1GRM5SPRUSP2 | |
| SCHEMBL322478 | 0.88 | GRM5 (0.49) | HSD11B1GRM5SPRUSP2 | |
| SCHEMBL1374546 | 0.87 | CTSB (0.41) | HSD11B1GRM5SPRUSP2 | |
| SCHEMBL3379327 | 0.85 | CTSB (0.38) | HSD11B1GRM5SPRUSP2 | |
| SCHEMBL29622544 | 0.85 | GRM5 (0.44) | HSD11B1GRM5SPR | |
| SCHEMBL31706968 | 0.82 | USP2 (0.45) | HSD11B1SPRUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220306588-A1 | BEZIMIDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2022-09-29 | — | — | US | claimed |
| US-20200207720-A1 | BEZIMIDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2020-07-02 | — | — | US | claimed |
| US-20220119412-A1 | THIAZOLOPYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220306588-A1 | BEZIMIDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | ADORA1, ADORA2A, ADORA3 | HSD11B1 3718/4885GRM5 1861/4885SPR 4674/4885 |
| US-20200207720-A1 | BEZIMIDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | ADORA1, ADORA2A, ADORA3 | HSD11B1 3718/4885GRM5 1861/4885SPR 4674/4885 |
| US-20220119412-A1 | THIAZOLOPYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | ADORA1, ADORA2A, ADORA3 | HSD11B1 3207/4885GRM5 1208/4885SPR 2547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.